$7.09
0.426.3%
Last update: Oct 28, 6:19 PM
Emergent BioSolutions Inc
EBSNYSE
Emergent BioSolutions (EBS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Emergent BioSolutions (EBS) last issued guidance on August 5, 2026 for Q3 2026. The company guided revenue in the range of $110M - $130M for the period.
Compared to prior guidance, Emergent BioSolutions lowered its revenue forecast from a prior range of $645M - $675M.
Emergent BioSolutions has issued 24 guidance updates between November 8, 2022 and August 5, 2026. During this period, the company raised its outlook 5 times and lowered it 9 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.11 | $-0.25 | $0.32 | $-0.03 |
| Actual | $0.60 | $0.21 | $-0.43 | $1.06 |
| Surprise | +445.5% | +184.0% | -234.4% | +3633.3% |
| Revenue | ||||
| Estimate | $179.4M | $157.4M | $216.5M | $198.6M |
| Actual | $234.3M | $156.1M | $148.7M | $231.1M |
| Surprise | +30.6% | -0.83% | -31.3% | +16.4% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.40 | $-0.10 | $-0.53 | $0.23 |
| Revenue | ||||
| Consensus | $123.2M | $142.7M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.60 | $0.11 | 445.5 % |
| Q1 | Apr 30, 2026 | $0.21 | $-0.25 | 184.0 % |
| Q4 | Feb 26, 2026 | $-0.43 | $0.32 | -234.4 % |
| Q3 | Oct 29, 2025 | $1.06 | $-0.03 | 3633.3 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $234.30M | $179.40M | 30.6 % |
| Q1 | Apr 30, 2026 | $156.10M | $157.40M | -0.83 % |
| Q4 | Feb 26, 2026 | $148.70M | $216.50M | -31.3 % |
| Q3 | Oct 29, 2025 | $231.10M | $198.60M | 16.4 % |
